المساء
Source: المساء
Recentlyالمساء
Source: المساء
RecentlyReady to play
Ready to play
Arzqi Chkaoui, director of biotechnological and pharmaceutical operations at Saidal Group, announced that Algeria is preparing to launch the first phase of local vaccine manufacturing, following negotiations that are still under way with German company Syntegon over the equipment. Current production is limited to the secondary packaging of influenza vaccines. The group is moving toward producing next-generation vaccines, including recombinant vaccines based on biotechnology, while working to meet export requirements. These include bringing the regulatory system up to Level 3 and obtaining prequalification for manufacturers. Chkaoui said that meeting these requirements could enable Algeria to take part in UNICEF tenders to supply vaccines to Africa, worth up to $3 billion a year, and advance its ambition to become an African pharmaceutical hub.
Notice: This Is an AI-Generated Summary
Comments (0)